 
  
 [STUDY_ID_REMOVED]  
HepB -CpG series for healthcare workers who are hepatitis B 
vaccine nonresponders  
6/11/2020  
~ i ~  
 
 
 
 
  
 
HepB -CpG series for healthcare workers who are hepatitis B vaccine nonresponders  
 
 
 
Protocol Number: UW HSC -IRB #2020 -0631  
Principal Investigator: [INVESTIGATOR_71415] S. Hayney, PharmD, MPH  
  
 
  
Dynavax  is supplying Heplisav -BTM for this study.  
  
[This document is confidential.  
No part of it may be transmitted, reproduced, published, or used by [CONTACT_678073]. ] 
  
 
Protocol Version History  
 
Protocol 
Version  Version 
Date  Summary of Revisions Made  Rationale  
1.0 05/28/2020  Initial version   
2.0 6/11/2020  Edits regarding AE notification and added 
Data collection form  Required elements  
    
    
    
    
    
  

- i -  
REMINDER: update the Table of Contents before considering the document or draft final. To update the Table of 
Contents , right click anywhere below and then select “ Update Field.”   
 
Table of Contents  
 
1.[ADDRESS_1103674] SELECTION  ............................................................................................................................ 6  
 Inclusion & Exclusion Criteria  ................................................................................................ ........ [ADDRESS_1103675] Identification  ................................................................................................ ..................... 6  
8 Error! Bookmark not defined.  
8.4.[ADDRESS_1103676] (EMR) Query  ............................................................................................................ 6  
 Error! Bookmark not defined.  
 Subject Recruitment  ................................................................................................ ...................... 7  
8.5.1  Recruitment through Employee Health  ............................................................................................................... 7  
 Error! Bookmark not defined.  
8.5.2 Email ................................................................................................................................................................... 7  
8.5.3 Telephone Recruitment  ....................................................................................................................................... 7  
 Remuneration and Retention Strat egies  ................................................................ ........................ 7  
 Early Termination and Withdrawal  ................................................................................................ . 7 
9.
0 STUDY AGENT (STUDY DRUG, DEVICE, BIOLOGIC, VACCINE, ETC.) AND/OR PROCEDURAL 
INTERVENTION  ....................................................................................................................................... 8  
 Study Agent and Control Description  ................................................................ ............................. 8  
9.1.1  Source ................................................................................................................................................................ 8  
9.1.2  Packaging and Labeling  ...................................................................................................................................... 8  
9.1.3  Preparation  ......................................................................................................................................................... 8  
9.1.4  Storage and Stability  ........................................................................................................................................... 8  
9 Error! Bookmark not defined.  
9.1.5 Dosing and Administration  .................................................................................................................................. 8  
 Error! Bookmark not defined.  
 Error! Bookmark not defined.  
 Error! Bookmark not defined.  
 Error! Bookmark not defined.  
 Error! Bookmark not defined.  
10.0  STUDY VISITS AND PROCEDURES  ....................................................................................................... 9  
- ii - 
 Study Calendar  ............................................................................................................................. 9  
 Screening and Enrollment  ................................................................................................ ............. 9  
10.2.1  Pre-screening  ...................................................................................................................................................... 9  
10.2.2  Informed Consent  ............................................................................................................................................... 9  
 Error! Bookmark not defined.  
 Error! Bookmark not defined.  
10.2. 3 Enrollment  ......................................................................................................................................................... 10 
10.2. 4 Screen Failure and Re-enrollment  .................................................................................................................... 10 
 On-Study/Follow -up Visits  ........................................................................................................... 10 
10.3.1  Visit Number  1 .................................................................................................................................................. 10 
10.3.2  Visit Numbe r 2 .................................................................................................................................................. 10 
10.3.3  Visit Number  3 .................................................................................................................................................. 10 
  
 Error! Bookmark not defined.  
 Unscheduled Visits  ...................................................................................................................... 11 
 Early Termination/Withdrawal Visit  .............................................................................................. 11 
 
11.
0 CORRELATIVE | SPECIAL STUDIES .................................................................................................... [ADDRESS_1103677] KEEPI[INVESTIGATOR_1645]  .............................................. 11 
 Data Collection  ............................................................................................................................ 11 
12.1.1  Data Collection Forms  ...................................................................................................................................... 11 
 Error! Bookmark not defined.  
 Confidentiality and Privacy  .......................................................................................................... 12 
 Records Retention  ...................................................................................................................... 12 
  ................................
....................................................................... Error! Bookmark not defined.  
 Error! Bookmark not defined.  
 Error! Bookmark not defined.  
   
 e Error! Bookmark not defined.  
 Protocol Deviations  ..................................................................................................................... 13 
 Publication and Data Sharing Policy  ............................................................................................  13 
  ................................
...................... Error! Bookmark not defined. Error! Bookmark not defined.  
  
 
 Error! Bookmark not defined.  
3.0STUDY ANALYSIS  .................................................................................................................................... [ADDRESS_1103678] Population(s) for Analysis  ............................................................................................... 13 
 Statistical Methods  ...................................................................................................................... 14 
14.0 R
ISK/BENEFIT ASSESSMENT  ............................................................................................................. 14 
 Potential Benefits to the Subjects  ................................................................................................ 14 
 Known Potential Risks  ................................................................................................................. 14 
14.2.1 Known Procedural Risks  ................................................................................................................................... 14 
14.2.2 Known Interventional Risks  ............................................................................................................................... 14 
15.0 DATA AND SAFETY MONITORING  ...................................................................................................... 14 
 Adverse Event (AE) Definition ..................................................................................................... 14 
 Serious Adverse Event (SAE) Definition ...................................................................................... 14 
- iii - 
 Classification of an Adverse Event  .............................................................................................. 15 
15.3.1 Severity of Event  ............................................................................................................................................... 15 
15.3.2 Relationship to Study, Study Procedure(s) and/or Study Intervention  .............................................................. 15 
15.3.3 Expectedness for Study, Study Procedure(s) and/or Study Intervention  .......................................................... 16 
 Time Period and Frequency for Event Assessment and Follow- Up ............................................. 16 
 Reporting AEs and SAEs  ............................................................................................................ 16 
16.5.1  Reporting AEs  ................................................................................................................................................... 16 
16.5.2  Reporting SAEs  ................................................................................................................................................ 16 
Unanticipated Problems  ................................................................................................................... 17 
16
.0 STUDY FEASIBILITY  .................................................................... ERROR! BOOKMARK NOT DEFINED. 
 Economic Burden to Subjects  ..................................................................................................... 18 
 Facilities and Locations  ............................................................................................................... 18 
 Feasibility of Recruiting the Required Number of Subjects  .......................................................... 18 
 Principal Investigator [INVESTIGATOR_799855]  .......................................................................................... 18 
17.4.1  Time Devoted to Conducting the Research  ...................................................................................................... 18 
17.4.2  Process for Informing Study Teams  .................................................................................................................. 18 
 Availability of Medical or Psychological Resources  ..................................................................... 18 
17.0 RE
FERENCES  ....................................................................................................................................... 18 
18.0  APPENDICES ........................................................................................................................................ 18 
 Data collection form ..................................................................................................................... 19 
 
 
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103679] of this study are informed about their 
obligations in meeting the above commitment.  
 
Name  [CONTACT_799881] S. Hayney, PharmD, MPH  
__________________________________ _____________________________ ___________________ 
Principal investigator  
 
 
 
 
 
 
  
[INVESTIGATOR_799856] B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103680] OF ABBREVIATIONS  
 
AE Adverse Event  
antiHBs  Antibody to the hepatitis B surface antigen  
CFR Code of Federal Regulations  
CRF Case Report Form  
CTCAE  Common Terminology Criteria for Adverse Events  
DHHS  Department of Health and Human Services  
DMC  Data Monitoring Committee  
DSMB  Data & Safety Monitoring Board  
DSMC  Data & Safety Monitoring Committee  
DSMP  Data & Safety Monitoring Plan  
eCRF  Electronic Case Report Forms  
EDC  Electronic Data Capture  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
HepB -CpG  Hepatitis B vaccine with CpG adjuvant (Heplisav -BTM) 
HIPAA  Health Insurance Portability and Accountability Act  
ICTR  Institute for Clinical and Translational Research  
IND Investigational New Drug Application  
IRB Institutional Review Board  
MOP  Manual of Procedures  
NCI National Cancer Institute  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
PHI Protected  Health Information  
PI [INVESTIGATOR_799857], Multisite, Accelerated Resources for Trials IRB  
SMC  Safety Monitoring Committee  
SMP  Study Monitoring Plan  
SMS  Study Monitoring Service  
UP Unanticipated Problem  
 
 
 
 
  
 
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 2 of 2 
  
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 1 of 19 
   
3.0 STUDY SUMMARY  
 Synopsis 
 
Full Title HepB -CpG series for healthcare workers who are hepatitis B vaccine nonresponders  
Short Title  Vaccination for healthcare worker hepatitis B vaccine nonresponders  
Protocol Number  [HS IRB 2020 -0631 ] 
ClinicalTrials.gov 
Identifier & 
Summary  pending  
This study is being done to determine if healthcare workers who have previously failed to respond to hepatitis B vaccine series will respond to a hepatitis B with CpG adjuvant  (hepB -
CpG)  (Heplisav -B) 
Number of  
Site(s)  The study will be conducted at UWHealth Employee Health Services  
Phase  Phase 4  
Main Inclusion  
Criteria  • Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine 
with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the 
hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.   
• English -speaking (able to provide consent ) 
Main Exclusion 
Criteria  • Allergy to hepB -CpG or a component  
Objective (s)  Primary Objective  
• To measure the number of healthcare workers who failed to respond to 5 or more doses 
of hepatitis B vaccine with aluminum adjuvant who will respond to hepatitis B vaccine 
with CpG adjuvant series.  
Secondary Objectives   
• To measure the number of healthcare workers who respond to a single dose of hepB -
CpG 
• To determine risk factors associated with hepatitis B vaccine nonresponse, including age, 
smoking status, sex, diabetes, immunosuppression 
 
Endpoints  Primary Endpoint  
• AntiHBs >10 mIU/ml following two doses of hepB- CpG 
Secondary Endpoint  
• AntiHBs >10 mIU/ml following a single dose of hepB- CpG  
 
• Measure effect of known hepatitis B vaccine nonresponse risk factors on response in this 
population 
Study Design  Open label  
IND or IDE 
Number  Not applicable 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103681] antiHBs < 10mIU/ml.   
Statistical 
Methodology  We will count the number of individuals who seroconvert and have anti -HBs >10 mIU/ml and 
report a ratio with the total number immunized as the denominator.   We will develop a multivariate model to predict hepB- CpG response which will include age, sex, smoking 
status, d iabetes, and immunosuppression as variables.  
Estimated 
Subject  Duration  The duration of the study for each subject is approximately 8 weeks.  
Estimated 
Enrollment 
Period & Study 
Duration  Study enrollment  and follow -up will occur over 12 months . 
   
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103682] 5 doses of hepatitis B 
vaccine with aluminum adjuvant and antiHBs <10 MIU/ml  
Eligible individuals will be invited to participate by [CONTACT_799868] 
(EHS) personnel.  
 
Draw blood for antiHBs  
Perform baseline assessments  and vaccine screening . 
Administer hepB -CpG by [CONTACT_799869] 1  
Time Point  
 
Visit 3 
Time P oint
Visit 2 
Time Point  
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103683] of all key personnel and roles: 
 
Principal Investigator  [INVESTIGATOR_71415] S. Hayney, PharmD, MPH  
Professor of Pharmacy  
University of Wisconsin School of Pharmacy  
[ADDRESS_1103684], Madison, WI [ZIP_CODE]  
[PHONE_16701]  
Participating Site(s)  UWHealth  Employee Health Services  
[ADDRESS_1103685]  
Madison, WI [ZIP_CODE]   
Funding Sponsor  (Supplying vaccine only)  Dynavax  
[ADDRESS_1103686]  
Emeryville, CA [ZIP_CODE]  
5.0 INTRODUCTION  
 Disease Background  
Although the recombinant hepatitis B (hepB) vaccine with aluminum adjuvant as a three dose series 
induces seroprotection in about 95% of individuals, a small number of healthy individuals fail to mount an 
immune response.  Increasing age is an important risk factor for hepB vaccine response. 1  Healthcare 
personnel are among the individuals for whom protection from hepatitis B infection is very important.  
Employee Health Service (EHS) at the University of Wisconsin Hospi[INVESTIGATOR_799858] 3 -dose series for antibody to the hepatitis B 
surface antigen (anti -HBs) at time of hire.  Those who are found to have anti -HBs less than 10 mIU/ml 
receive a challenge dose. 2  If the anti -HBs remains  less than 10 mIU/ml, two more doses of vaccine are 
administered.  Among the 15,[ADDRESS_1103687] completed two hepB vaccine with 
aluminum adjuvant series but remain vaccine non -responders.  Heplisav -B (hepB -CpG) is a recently 
licensed hepB vaccine with a new adjuvant that is more immunogenic in the general adult population and 
patients with chronic kidney disease or diabetes.3- 5  Given the superior immunogenicity of hepB -CpG in 
these individuals who were difficult to induce seroprotection, we hypothesize that 70% of the [ADDRESS_1103688]  of Care 
With the recent licensure of hepatitis B vaccine with CpG antigen, the Advisory Committee on 
Immunization Practices (ACIP) has recommended this vaccine series as a vaccine that can be used for 
adults for whom hepatitis B immunization is recommended.  This vaccine series is more immunogenic in 
the general adult population and patients with chronic kidney disease or diabetes.  The ACIP has listed hepB -CpG as a vaccine that can be used for revaccination.   
 
 Investigational  Treatment  
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103689] of care rather than an option among all hepatitis B vaccine 
preparations.  
6.0 STUDY OBJECTIVES AND ENDPOINTS  
 
Objectives  Endpoints  
Primary  
To measure the number of healthcare 
workers who failed to respond to 5 or 
more doses of hepatitis B vaccine with 
aluminum adjuvant who will respond to 
hepatitis B vaccine with CpG adjuvant 
series  antiHBs > 10mIU/ml after completion of the 
series  
Secondary  
To measure the number of healthcare 
workers who respond to a single dose of hepB -CpG 
 antiHBs > 10mIU/ml after one dose of hepB -CpG 
To determine risk factors associated with 
hepatitis B vaccine nonresponse, including age, smoking status, sex, 
diabetes, immunosuppression 
 Proportion of participants who are nonresponders 
with each risk factor and develop a multivariate 
model  
 
7.[ADDRESS_1103690] antiHBs < 10mIU/ml.   
 
The study population will consist of [ADDRESS_1103691] antiHBs < 10mIU/ml.   
 All study visits will be done at Employee Health Services.  During visit 1, written informed consent for participation will be obtained.  Each participant will be screened for vaccine contraindications.  Participants 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 6 of 19 
 will be briefly interviewed for known hepatitis B vaccine nonresponse risk factors —age, sex, smoking 
status, diabetes, and immunosuppression. 
 
Each participant will receive hepB- CpG intramuscularly at visit [ADDRESS_1103692] a blood draw for 
antiHBs and receive hepB -CpG dose 2 intramuscularly.  A blood draw for antiHBs will be done at visit 3 
one month following dose 2.  The vaccine administration will be documented in the Wisconsin Immunization Registry (the WIR) and the antiHBs results will be retained in the Employee Health electronic 
medical record (Agility).   
 
Subject accrual will occur over [ADDRESS_1103693]  SELECTION  
 Inclusion & Exclusion Criteria    
 Eligibility will be determined by [CONTACT_799870]. 
 
Inclusion Criteria  
1. Willing to provide informed consent.  
2. Willing to comply with all study procedures and be available for the duration of the study.  
3. healthcare workers who have received at least [ADDRESS_1103694] antiHBs < 10mIU/ml  
4. Individuals at least [ADDRESS_1103695] (EMR) Query  
Potential subjects will be identified via Agility  (the EMR used by [CONTACT_799871]) query .  Eligible individuals are 
flagged in the system as they require special prophylaxis following bloodborne pathogen exposures.  The research team will conduct further prescreening of individual records to further refine the list of 
potential subjects.   
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103696] Recruitment  
Up to 130  subjects will be recruited from UWHealth . Specific recruitment strategies are as follows (non-
comprehensive list):  
8.3.[ADDRESS_1103697] the study team , a brief description of the study’s purpose and 
participation requirements will be reviewed. This must also include a statement that participation is 
voluntary. The screener will ask the caller if s/he has any questions and about interest in participating. 
After all questions have been answered, the study team member will ask if the potential subject is 
interested in proceeding to the next step in recruitment for the study (e.g. , scheduling a visit to learn 
more and go through the consent process, or answering some screening questions) .] 
 Retention Strategies  
Strategies for retention include:  
• Appointment for the next visit will be set at the end of each visit  
• Email visit reminder 3 days prior to visit and day prior if appointment is before 10am or day of visit if 
visit is at 10am or later.  
• Recall reminders for missed appointment.  Each participant will be contact[CONTACT_799872] 2 days apart.  
• Flexible study visit windows  and be used with the following limits to accommodate subject schedules.   
Time between visits [ADDRESS_1103698].  
 
The Principal Investigator (PI) may discontinue or withdraw a subject from the study f or the following 
reasons at her discretion:  
• Pregnancy  
• Subject non- compliance with study requirements (e.g., study intervention non- compliance)   
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs 
such that continued participation in the study would not be in the best interest of the subject  
• If the subject  is no longer an appropriate candidate for participation   
 
The following actions must be taken if a subject withdraws, or  fails to return for a required study visit:  
• The site will attempt to contact [CONTACT_799873] 
8.[ADDRESS_1103699]  wishes to and/or should continue in the study.  
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 8 of 19 
 • Before a subject  is deemed lost to follow -up, the investigator or designee will make every effort to 
regain contact [CONTACT_799874] 8.[ADDRESS_1103700] attempts shall  be documented 
the study file.  
• If the subject  continues to be unreachable, s/he  will be considered to have withdrawn from the study 
with a primary reason of lost to follow- up. The withdrawn date is the last day of attempted contact . 
 
9.0 STUDY AGENT (STUDY DRUG, DEVICE,  BIOLOGIC, VACCINE, ETC.) AND/OR PROCEDURAL 
INTERVENTION  
 Study Agent and Control Description  
Study Product  
 Recombinant hepatitis B vaccine with CpG adjuvant  (Heplisav -B, Dynavax)  
9.1.[ADDRESS_1103701] receipt will use departmental procedures for unpacking and storing the vaccine, including checking that the cold chain 
was maintained during shipment (i.e., verification of the temperature indicator). The contents of the 
shipment will then be reviewed and verified against the packing slip, and will be documented as 
instructed at the initiation visit.  
 If the temperature -monitoring indicator reflects that the cold chain has been broken, the entire shipment 
must be immediately quarantined.  The principal investigator [INVESTIGATOR_799859].  
9.1.2  P
ackaging and Labeling 
• The vaccine will be supplied as the commercial product and labeled as such.   
 
9.1.3  P reparation  
The vaccine will be supplied as a single- dose prefilled syringe.   
 
9.1.4  Storage and Stability  
Storage Conditions  
Store in a refrigerator at 2°C to 8°C (36°F to 46°F).  
Do not freeze; discard if the vaccine has been frozen.  
9.1.5  Dosing and Administration 
HepB -CpG will be supplied as 0. 5 mL single -dose, pre- filled syringes. No preparation is required. 
Administer as follows:  
 
• Visually inspect the syringe for particulate matter and/or discoloration prior to administration. If either of these conditions exist, do not administer  
• Gently shake the prefilled syringe  
• Identify the deltoid muscle (upper arm) and cleanse the injection site with alcohol  
• Insert needle (22 to 25 -gauge 1- inch needle recommended; 1 ½ inch needle recommended for 
those with BMI ≥ 30) at a [ADDRESS_1103702] entire contents of the syringe 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103703] the vaccine subcutaneously or intravenously. Care should be taken to 
avoid administering the injection into or near blood vessels and nerves. 
• Monitor the subject for at least [ADDRESS_1103704] administration] 
10.0 STUDY VISITS  AND PROCEDURES  
 Study Calendar  
The procedures performed at each study visit are listed in the table below.  
 
Procedure  Visit 1  Visit 2 Visit 3  
End of 
study/early 
withdrawal  
Visit Window  Day 0 Day 28- 42 Day 28 -42 
following 
visit 2   
Informed Consent  X   
Review Eligibility Criteria  X   
Demographics1 X   
Obtain Medical History2 X   
Vital Signs3 X X X 
Vaccine screening  X X  
Vaccine  administration  X X   
Blood draw   X X 
Adverse Events 
Review/Assessment    X X 
[ADDRESS_1103705] antiHBs < 10mIU/ml  
10.2.2  I
nformed Consent  
Preliminarily eligible subjects will be invited to EHS  for informed consent and formal screening. The 
informed consent process will be conducted following all federal and institutional regulations relating to informed consent. Informed consent will be obtained prior to conducting any study -related activities.  
 The informed consent process will be performed as follows:  
• The principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a co -investigator  will review the informed consent form and discuss the 
study in detail with the potential research subject.  
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 10 of 19 
 • The principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a co -investigator  will explain the study, its risks and benefits, what 
would be required of the research subject, and alternatives to participation. 
• The research subject will be given the opportunity to take the informed consent form home so that 
s/he may discuss it with family members, friends, clergy or others when possible.   
• The subject will have the opportunity to ask questions and have all questions answered by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a co- investigator . 
• The informed consent document must be signed and dated by [CONTACT_2330].  
• The principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] a co -investigator  will review the informed consent document to ensure 
that all fields that require a response are complete (i.e., checkbox marked yes or no, etc.) as applicable.  
• The research subject will be given a copy of the signed and dated informed consent form. The original signed informed consent form is kept the study binder.  
10.2.[ADDRESS_1103706] will be defined as “enrolled” in the study when they meet  the following criteria:  
• The subject has been consented by [CONTACT_464].  
• The subject and study staff have completed all screening documentation.  
• The study staff  has verified that the subject meets all of the inclusion criteria.  
• The study staff  has verified that subject meets none of the exclusion criteria.  
• The subject has been assigned to the protocol by [CONTACT_464].  
• The subject has scheduled a study visit  which can follow the informed consent process described 
above. 
10.2.4  S creen Failure and Re -enrollment  
Individuals who do not meet the criteria for participation in this trial (screen failure) because of a possible pregnancy  may be rescreened. Rescreened subjects should be assigned a new subject ID 
number when they are re -screened . 
 On-Study /Follow- up Visits  
After subjects have been enrolled, the On -Study/Follow -up visit and the procedures performed at each visit  
are described in detail below.  
10.3.1  V isit Number  1  
The following activities will be done during visit 1 which can directly follow the informed consent and 
enrollment phases.  
• Limited interview for medical history to collect age, sex, race, ethnicity, and self -reported 
smoking history, diabetes and immunosuppression.  Hepatitis B vaccine history and antiHBs dates , UWHealth department and location will be collected from Agility, the EHS EMR.  
(research)  
• Vitals (per EHS routine)  
• Vaccine screening (research)  
• Vaccine administration and aftercare (research)  
Visit 1 is expected to take about 45 minutes.  
10.3.2  V
isit Number  2 
The following activities will be done during visit 2 which is done 28 -42 days after visit 1.  
• Vitals (per EHS routine)  
• Ask about adverse events following hepB -CpG.  Report to VAERS if appropriate (routine) 
• Blood draw for antiHBs (research)  
• Vaccine screening (research)  
• Vaccine administration and aftercare (research)  
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 11 of 19 
 Visit 2 is expected to take about 30 minutes.  
 
10.3.3  V isit Number  3  
The following activities will be done during visit 3 which is done 28 -42 days after visit 3.  
• Vitals (per EHS routine)  
• Ask about adverse events following hepB -CpG.  Report to VAERS if appropriate (routine) 
• Blood draw for antiHBs (research)  
• Dismiss from study participation with information that EHS employee will contact [CONTACT_799875] (research)  
Visit 3 is expected to take about 15 minutes.  
 
 Unscheduled Visits  
Unscheduled visits  will not occur for this study.  
 Early Termination/ Withdrawal  Visit  
Subjects who are either withdrawn or terminated early from the study will have one final visit to to follow up 
regarding adverse events . 
11.0 CORRELATIVE | SPECIAL STUDIES  
 Biospecimen Collection Guidelines  
Standard phlebotomy procedures to collect 3ml in red top with yellow ring and sent to the UWHealth 
Clinical Lab for antiHBs.   
 Assay Methodology  
  
The UWHealth Clinical Laboratory uses a chemiluminescent immunoassay to measure antiHBs.  
12.[ADDRESS_1103707] KEEPI[INVESTIGATOR_192884]  
 
12.1.1  Data Collection Forms  
Standardized data collection forms (e.g., source documents, case report forms, standardized assessment forms, etc.) are used to ensure data collected are consistent and compliant with the 
protocol and IRB application.  
 Data collection is the responsibility of study team members under the supervision of the Principal 
Investigator  (PI). The PI  [INVESTIGATOR_19760], completeness, legibility, and 
timeliness of the recorded and reported data.  Data will be collected from the participant and the EHS 
EMR as described in Section 10.  
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103708] be completed in a legible manner; any missing data will be explained. 
Data entry errors will be corrected with a single line through the incorrect entry and the correct data is 
entered above/near the correction. All changes will be initialed and dated.  
 
Data collection forms are maintained in the subject files and retained as described in Section 12.3: 
Records Retention. 
 Confidentiality and Privacy 
Subject  confidentiality and privacy is strictly held in trust by [CONTACT_92923] .  
The sponsor will have no access to the study data.  This confidentiality is extended to cover testing of 
biological samples and to the clinical information relating to subject s. Therefore, the study protocol, 
documentation, data, and all other information generated will be held in strict confidence.  
 All research activities will be conducted in as private a setting as possible.  
 
All study staff engaged in the conduct of this project have completed  training on the protection of human 
subjects and the Health Insurance Portability and Accountability (HIPAA) Privacy Rule. In a ddition, all key 
personnel (i.e. ., Principal Investigator, individuals involved in identifying/recruiting subjects, obtaining 
informed consent, or interacting and intervening with subjects ) have undergone Good Clinical Practice 
(GCP) training.  
 
Information about study subjects will be kept confidential and managed according to HIPAA requirements. 
All subjects will a combined informed consent and HIPAA authorization form that includes specific privacy and confidentiality rights. Study data will be maintained per federal, state, and institutional data policies.  
 The investigator(s) will ensure that the identities of subjects are protected by [CONTACT_799876]. The log of subject identifying information that links subjects to their study -specific identification 
number will be maintained by [CONTACT_093]. The log and all study records will be maintained in locked rooms  and access will be limited to essential study personnel. Electronic study records/files will be stored 
on a School of Pharmacy  server and accessed via networked computers that are pass word -protected with 
access provided only to authorized study personnel.   
Authorized representatives of the following groups may need to review this research as part of their 
responsibilities to protect research subjects: representatives of the IRB and federal oversight agencies, 
such as the Food and Drug Administration ( FDA). The clinical study site will permit access to such records.  
 
Study staff may use e -mail to communicate with research subjects, if the subject has agreed to using email 
in the Informed Consent form. The information contained in emails will be limited to study visit time and 
date information and general questions. All emails to subjects will be sent from UW/wisc.edu or uwhealth 
accounts; personal, home or Gmail email accounts will not be used. 
 
 Records Retention  
It is the investigator’s responsibility to retain study essential documents for a minimum period of [ADDRESS_1103709].  
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103710], the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_48162].  
 It is the responsibility of the Principal Investigator  [INVESTIGATOR_799860]. The Principal Investigator [INVESTIGATOR_799861].   
 Publication and Data Sharing Policy  
The Principal Investigators will work with the co -investigators to draft a manuscript for publication regarding 
the findings of this study.  All precautions will be taken to avoid identification of an research participant in the publication.   
13.0 STUDY ANALYSIS  
 Statistical Hypotheses  
• Primary Efficacy Endpoint(s):  
AntiHBs >10 mIU/ml following two doses of hepB- CpG 
Descriptive statistics will be used to report the result, including number of responders and ratio of 
responders.   
 
• Secondary Efficacy Endpoint(s):  
AntiHBs >10 mIU/ml following two doses of hepB- CpG 
Descriptive statistics will be used to report the result, including number of responders and ratio of 
responders.    Proportion of participants who are nonresponders with each risk factor and develop a multivariate 
model  
Descriptive statistics will be used to report the result for each risk factor, including number of 
responders and ratio of responders.  Multivariate analysis will be used to develop a model.  
 
 
 Sample Size Justification 
In an effort to be fair to all potentially eligible UWHC healthcare workers, we want to offer the hepB -CpG 
vaccine series to all known eligible individuals (those who have failed to respond to at least 5 doses of 
hepatitis B vaccine with aluminum adjuvant) .   
 
 Subject Population(s) for Analysis  
Analyses will include all individuals who received at least one dose of hepB -CpG.  We will also do a per -
protocol analysis for hepB- CpG one dose and two doses.   
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/[ADDRESS_1103711] to known risk factors for hepatitis B vaccine nonresponse.  A multivariate model 
with the risk factors will be developed.  
   
14.0 RISK/BENEFIT ASSESSMENT  
 Potential Benefits to the Subjects  
The potential benefits to research subjects associated with this study include participants’ safety as healthcare providers should they be converted to hepatitis B vaccine responders.   
 If hepB -CpG has a high response rate, this vaccine could become the preferred vaccine series for 
nonresponders.   
 
 Known Potential Risks  
14.2.1  Known Procedural Risks 
Procedure : Risk description(s)  
 
• Blood Draw : The risks of drawing blood from a vein include discomfort at the site of puncture; 
possible bruising and swelling around the puncture site; rarely an infection; and, uncommonly, 
faintness from the procedure.  
14.2.2  K nown Interventional Risks 
. 
• HepB -CpG:  Risks of hepatitis B immunization include soreness at the injection site , fever,  or 
fainting.  Anaphylaxis occurs very rarely.  No information regarding hepB- CpG during pregnancy is 
available.   
Hepatitis B immunization is recommended for all healthcare workers at risk for bloodborne pathogens 
exposure.  Repeated series, including the use of hepB -CpG series, is one strategy to convert 
nonresponders to responders so participation in this study conforms with current immunization recommendations for healthcare providers.  (Heplisav -B package insert, Vaccine Information Statement 
published by [CONTACT_6750])  
15.0 DATA AND SAFETY MONITORING  
 Adverse Event  (AE) Definition  
Adverse event (AE) means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention -related.  
 Serious Adverse Event (SAE)  Definition  
An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it meets any of 
the following criteria:  
• Results in death  
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 15 of 19 
 • Is life -threatening  
• Requires an inpatient hospi[INVESTIGATOR_1324]  
• Results in persistent or significant disability or incapacity.  
• Results in a congenital anomaly/birth defect.  
• A medical event, based on appropriate medical judgment, that is believed to jeopardize the subject  
and/or requires medical or surgical intervention to prevent one of the outcomes defining a SAE. For 
example: allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
convulsions that may not result in hospi[INVESTIGATOR_799862]  
15.3.1  Severity of Event  
All AEs will be a ssessed by [CONTACT_799877] 
(CTCAE), version 5.0 , each event searchable using the Safety Profiler website (https://safetyprofiler -
ctep.nci.nih.gov/CTC/CTC.aspx) . For AEs not included in the protocol -defined grading system, the 
following guidelines will be used to describe severity.   
 
Mild 
(Grade 1)  Events require minimal or no treatment and do not interfere with the subject’s daily activities.  
Moderate  
(Grade 2)  Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference 
with functioning.  
Severe 
(Grade 3)  Events interrupt a subject’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually 
potentially life -threatening or incapacitating.  
Life Threatening 
(Grade 4)  The subject was at risk of death at the time of the event.  
Fatal  
(Grade 5)  The event caused death.  
 
15.3.2  R elationship to Study, Study Procedure(s) and/or Study Intervention(s)  
 For all collected AEs, the clinician who examines and evaluates the subject will determine the AE’ s 
causality based on temporal relationship and his/her clinical judgment. The degree of certainty about 
causality will be gra ded using the categories below.  
 
Definitely Related  Clearly related to the study procedures/intervention and other 
possible contributing factors can be ruled out.  
Probably Related  Likely related to the study procedures/intervention  and the influence 
of other factors is unlikely.  
Possibly Related  Possibly related to the study procedures/intervention  and there are 
other factors that could be equally likely.  
Unlikely to be related  Doubtfully related to the study procedures/intervention and there is 
another likely cause.  
Unrelated  Clearly not related to the study procedures/intervention and/or 
evidence exists that the event is definitely related to another cause.  
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 16 of 19 
 15.3.3  Expectedness for Study, Study Procedure(s) and/or Study Intervention(s)  
The PI [INVESTIGATOR_799863](s) (as applicable).  
 
 
For studies not evaluating an investigational drug : An AE will be considered unexpected if the nature, 
severity, or frequency of the event is not consistent with the risk information previously described in the clinical protocol, the IRB application, or the informed consent document. The expectedness could be based on study procedures or the characteris tics of the patient population.  
 Time Period and Frequency for Event Assessment and Follow -Up 
 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits. All AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate 
CRF. Information to be collected includes event description, time of onset, clinician’s assessment of 
severity, relationship to study product (assessed only by [CONTACT_8703] a 
diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution. AEs 
will be reported to the Vaccine Adverse Event Reporting System (VAERS) as this is the standard of 
practice.  
 Any medical condition that is present at the time that the subject  is screened will be considered as baseline 
and not reported as an AE. However, if the study subject ’s condition deteriorates at any time during the 
study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at 
each level of severity to be performed. AEs characterized as intermittent require documentation of onset 
and duration of each epi[INVESTIGATOR_1865].  
 
The PI [INVESTIGATOR_799864] [ADDRESS_1103712] dose of study drug or at Visit 3 . At each study 
visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be 
followed for outcome information until resolution, stabilization, or completion of study participation.  
 Reporting AEs  and SAEs  
15.5.1  Reporting AEs  
The Principal Investigator [INVESTIGATOR_799865] a participant.  AEs will be reported to the Vaccine Adverse Event Reporting System (VAERS) as this is the standard of practice.  
15.5.[ADDRESS_1103713]  is stable.  
 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 17 of 19 
 The investigator  will be responsible for notifying the FDA of any unexpected fatal or life- threatening 
suspected adverse reaction as soon as possible and within the timeframes posted on the HS IRB 
website after the investigator 's initial receipt of the information.  
 
 Unanticipated Problems 
An unanticipated problem  (UP), as defined by [CONTACT_799878] (OHRP), is 
any incident, experience, or outcome that meets all of the following criteria:  
• The incidence, experience, or outcome is unexpected given the research procedures described in 
protocol -related documents (e.g., the study protocol,  the informed consent documents ) and the 
characteristics of the subject population being studied. An event may be considered unexpected if it exceeds the nature, severity, or frequency described in the study -related documents, product labeling, 
or package insert.  
• The incidence, experience, or outcome is related or probably related to participation in the research study. “Probably related” means the incidence, experience, or outcome is more likely than not to be 
caused by [CONTACT_666669].  
• The occurrence of the incidence, experience, or outcome suggests that the research places subjects or others at a greater risk of harm (physical, psychological, economic, or social) than was previously 
known or recognized.  
 
The investigator will report UPs to the reviewing IRB  within the timeframe posted on the HS IRB website. 
The UP report will include the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol, informed consent documents, or other corrective actions that have been taken or are proposed in response to the UP.  
 
 
 Protocol Deviations  
Refer to section 12.4. 
 Data Safety Monitoring Plan  
The study involves a small number of participants, is conducted at only one site, and/or the range of possible study events having an important impact on risks and benefits to participants is narrow, the 
principal investigator (PI) will perform the monitoring functions.  
 
    The type of data or events to be captured under the monitoring plan:  Reported adverse events by 
[CONTACT_799879] 2 and 3. Study accruals, protocol deviations, protocol violations, and unanticipated problems will also be monitored.  
    The name(s) of the person(s) who will be responsible for monitoring the data collected (i.e. study 
accruals, protocol deviations, protocol violations, unanticipated problems, adverse events) and their respective roles (e.g. investigators, research sponsor):  Mary Hayney, Principal Investigator, is responsible.  
    The frequency of assessments/analysis of data or events captured by [CONTACT_219680] (e.g. a 
periodic time interval or after a specific number of participants are enrolled):  Monitoring will be done 
monthly.   
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 18 of 19 
     The time frame for reporting unanticipated problems, adverse events, protocol deviations, and protocol 
violations.  These will be reported by [CONTACT_799880] [INVESTIGATOR_799866].  The PI [INVESTIGATOR_799867]. Reports to VAERS or FDA will be 
done at the same time. 
     Plans to monitor adherence to the IRB -approved protocol and assure the validity and integrity of data:  
The data collection forms and adverse event descriptions will be reviewed by [CONTACT_978] [INVESTIGATOR_78384].   
16.[ADDRESS_1103714] adjuvant compared with a licensed 
hepatitis B vaccine in adults. Vaccine. 2018;36(5):668- 674. 
2. Hyer RN, Janssen RS. Immunogenicity and safety of a 2 -dose hepatitis B vaccine, HBsAg/CpG 
1018, in persons with diabetes mellitus aged 60– 70 years. Vaccine. 2019;37(39):5854- 5861.  
3. Janssen RS, Mangoo- Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational 
hepatitis B vaccine with a toll -like receptor [ADDRESS_1103715] adjuvant (HBsAg- 1018) compared with a 
Vaccination for healthcare worker hepatitis B 
vaccine nonresponders   Hayney  
  
 
Version #: 1  Version Date : 6/2020  Page 19 of 19 
 licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31(46):5306 -
5313 
4. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United 
States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2018;67(RR No. -1):1-31. 
 
16.0 18 .0  APPENDICES  
18.1 Data collection form (appendix A)  
 
Data Collection Form  
Subject ID  
Date of birth  
UWH Dept  
UWH location  
Sex 
Race  
Ethnicity   
Diabetes yes/no  
Smoking yes/no/past  
Immunosup pression 
yes/no  
HepB dose 1  
HepB dose 2  
HepB dose 3  
antiHBs date  
antiHBs result  
HepB dose 4  
antiHBs date  
antiHBs result  
HepB dose 5  
HepB dose 6  
antiHBs date  
antiHBs result  
HepB -CpG dose 1  
antiHBs date  
antiHBs result  
HepB -CpG dose 2  
antiHBs date  
antiHBs result  
 